Logo

Acacia's Patent-Acquisition Subsidiary Licenses Nucleic Acid-Purification IP

Jun 11, 2007
This article corrects an earlier version that mistakenly reported that Acacia Technologies subsidiary CombiMatrix licensed the IP.
 
NEW YORK (GenomeWeb News) — Acacia Research Corporation last week said that Acacia Patent Acquisition Corporation, a wholly owned subsidiary of Acacia Technologies, has acquired rights to patents relating to purifying nucleic acids.
 
Acacia did not disclose the name of the entity that sold it the IP, but said that the patents “generally relate to methods and equipment used to purify plasmid DNA products.”
 
The company said the technology could be used to produce "ultrapure pharmaceutical quality nucleic acids for DNA-vaccines and gene therapies” for a variety of diseases.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.